Creo Medical AI Stock Analysis
Want to see GB:CREO full AI Analyst Report?
Creo Medical (CREO) AI Stock Analysis
Creo Medical
(LSE:CREO)
Low score driven mainly by weak financials from losses and cash burn despite balance sheet resilience, compounded by bearish technicals and unattractive valuation on negative earnings.
Creo Medical (CREO) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 46.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 714.73K
- Price to Earnings (P/E)
- -2.3
- Beta (1Y)
- 1.15
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- UK
- Employees
- 104
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Creo Medical Business Overview & Revenue Model
Company Description
Creo Medical Limited, a UK-based enterprise and subsidiary of Creo Medical Group plc, specializes in the innovation and creation of electrosurgical medical devices for surgical endoscopy applications. Founded in 2003 as MicroOncology Ltd and headquar...
How the Company Makes Money
Creo Medical makes money primarily through the sale of medical devices and associated consumables used in endoscopic procedures. Key revenue streams include: (1) Capital equipment/platform sales: revenue from selling its electrosurgical generator/sys...
Creo Medical Financial Statement Overview
Summary
Balance sheet offers stability via low debt and positive equity, but income statement and cash flow reflect persistent losses, negative margins, and heavy cash burn with revenue volatility; 2025 rebound projected.
Income Statement
35NegativeBalance Sheet
65PositiveCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.00M | 6.00M | 4.00M | 4.00M | 27.17M | 25.16M |
| Gross Profit | 1.90M | 1.40M | 1.90M | 15.30M | 10.01M | 9.02M |
| EBITDA | -19.70M | -19.70M | -26.10M | -20.70M | -27.62M | -27.54M |
| Net Income | 5.30M | 5.30M | -28.70M | -21.70M | -26.94M | -24.59M |
Balance Sheet | ||||||
| Total Assets | 59.10M | 59.10M | 65.00M | 76.60M | 75.34M | 100.61M |
| Cash, Cash Equivalents and Short-Term Investments | 12.40M | 12.40M | 8.70M | 18.50M | 13.10M | 43.53M |
| Total Debt | 4.10M | 4.10M | 4.40M | 8.30M | 11.70M | 10.56M |
| Total Liabilities | 9.10M | 9.10M | 22.60M | 16.80M | 25.93M | 27.29M |
| Stockholders Equity | 50.00M | 50.00M | 42.40M | 59.80M | 49.40M | 73.32M |
Cash Flow | ||||||
| Free Cash Flow | -18.90M | -20.00M | -22.60M | -22.80M | -28.26M | -32.10M |
| Operating Cash Flow | -18.90M | -19.10M | -22.20M | -21.60M | -24.99M | -25.98M |
| Investing Cash Flow | 19.40M | 19.40M | 15.30M | -18.30M | -6.03M | -7.87M |
| Financing Cash Flow | -700.00K | -700.00K | 16.20M | 29.80M | 400.00K | 31.99M |
Creo Medical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CREO, the sentiment is Negative. The current price of 10.25 is below the 20-day moving average (MA) of 10.90, below the 50-day MA of 11.22, and below the 200-day MA of 12.95, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 31.40 is Neutral, neither overbought nor oversold. The STOCH value of 7.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CREO.
Creo Medical Peers Comparison
Overall Rating
GB:TSTL80Outperform
GB:SN71.85Outperform
GB:AMS71Outperform
GB:SUN45Neutral
GB:CREO41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | GBP 188.69M | 23.53 | 23.05% | 3.62% | 10.02% | 19.83% | |
| 72Outperform | GBP 9.85B | 20.45 | 12.25% | 2.50% | 2.17% | 27.33% | |
| 71Outperform | GBP 617.83M | 166.76 | 1.44% | 1.65% | 6.05% | -60.00% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | GBP 3.73M | -4.00 | -15.47% | ― | -3.68% | 20.00% | |
| 41Neutral | GBP 46.04M | -2.26 | -38.29% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:CREO | Creo Medical | 10.25 | 0.00 | 0.00% | |
| GB:AMS | Advanced Medical Solutions | 283.50 | 73.45 | 34.97% | |
| GB:SUN | Surgical Innovations Group Plc | 0.40 | -0.18 | -31.03% | |
| GB:TSTL | Tristel plc | 392.50 | 41.36 | 11.78% | |
| GB:SN | Smith & Nephew (UK) | 1176.50 | -35.84 | -2.96% |
Creo Medical Corporate Events
Creo Medical Cuts Costs and Lifts Revenue as Endoscopy Devices Gain Traction
PositiveCreo Medical reported unaudited interim results for the six months to 30 June 2026 showing strong progress in tightening its cost base while accelerating commercial adoption of its advanced endoscopy tools. Revenue rose 45% to £3.2 million, underlyin...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
